Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

SIRIUS-LN

99 years and younger
All genders
This trial seeks to evaluates the efficacy, safety, and tolerability of ianalumab, compared to placebo, in achieving stable complete renal response at week 72 in adults with active lupus nephritis on background SoC therapy.
Learn More

TATE

99 years and younger
All genders
Primary: To determine the preliminary efficacy of TATE in the locoregional treatment of NET liver metastases using ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 and the DoR. Secondary: Determine the toxicity of TATE in NET patients with liver-dominant metastases Determine the PFS by mRECIST and …
Learn More

UPCC 19123 ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer

99 years and younger
All genders
Please refer to Protocol Section 1 (Objectives). Please refer to Protocol Section 14.3 (Analysis of Secondary Endpoints). Please refer to Protocol Section 14.1. (Study Design/Endpoints)
Learn More

UPCC 33923: Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 26423 Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCR and 4-1BB Signaling Domains in Combination with CD33KO-HSPC in Subjects with Refractory or Relapsed Acute Myeloid Leukemia

99 years and younger
All genders
Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints).
Learn More

UPCC 09422: Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia

99 years and younger
All genders
This study will randomly assign hospitals to deliver either specialty palliative care or primary palliative care for patients with AML. Our site will provide participants with specialty palliative care. This study will enroll patients, their caregivers, and key informants (health care clinician or leader) to provide perspectives on palliative care.
Learn More

UPCC 20222 Protocol to permit collection of circulating biomarkers in pancreatic cancer

99 years and younger
All genders
Please refer to Protocol
Learn More

Patent-B

99 years and younger
All genders
The primary objective is to determine the safety and efficacy of GIE Medicals ProTractX3 TTS DCB for the treatment of recurrent benign bowel strictures. The ProTractX3 DCB is intended to treat benign strictures of the alimentary tract, combining mechanical dilation with localized delivery of the drug paclitaxel. The goal of …
Learn More

UPCC 12223: A Phase 2, Open-label, Multicenter Study Investigating RP3 Oncolytic Immunotherapy in Combination with First- or Second-line Therapy in Patients with Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma

99 years and younger
All genders
Please refer to Protocol section 3 (Objectives and Endpoints). Please refer to Protocol section 3 (Objectives and Endpoints). Please refer to Protocol section 3 (Objectives and Endpoints).
Learn More

UPCC 09223: A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination with Atezolizumab and bevacizumab for the Treatment of Patients with Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma

99 years and younger
All genders
Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints)
Learn More
581 - 590 of 930